Details of the Drug Combination

General Information of Drug Combination (ID: DCMQL0X)

Drug Combination Name
MN-221 MN-221
Indication
Disease Entry Status REF
Asthma Phase 2 [1]
Component Drugs MN-221   DMBX2RE MN-221   DMBX2RE
Small molecular drug Small molecular drug
2D MOL 2D MOL
3D MOL is unavailable 3D MOL is unavailable

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of MN-221
Disease Entry ICD 11 Status REF
Aging skin EE40 Phase 2 [1]
Exacerbation of acute asthma CA23.30 Phase 2 [1]
MN-221 Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Adrenergic receptor beta-2 (ADRB2) TT2CJVK ADRB2_HUMAN Agonist [2]
------------------------------------------------------------------------------------
Indication(s) of MN-221
Disease Entry ICD 11 Status REF
Aging skin EE40 Phase 2 [1]
Exacerbation of acute asthma CA23.30 Phase 2 [1]
MN-221 Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Adrenergic receptor beta-2 (ADRB2) TT2CJVK ADRB2_HUMAN Agonist [2]
------------------------------------------------------------------------------------

References

1 ClinicalTrials.gov (NCT00683449) Study Evaluating the Safety and Effects of MN-221 in Subjects Experiencing an Acute Exacerbation of Asthma. U.S. National Institutes of Health.
2 Investigation of beta(2)-adrenoceptor subtype selectivity and organ specificity for bedoradrine (KUR-1246), a novel tocolytic beta-adrenergic receptor stimulant. J Obstet Gynaecol Res. 2009 Jun;35(3):405-13.